Ironwood Pharma (IRWD) Tops Q1 EPS by 5c, provides guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $106.51 million versus the consensus estimate of $92.11 million.

GUIDANCE:

Ironwood Pharma sees FY2026 revenue of $450-475 million, versus the consensus of $458.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• CalPrivate Bank names Andra Frazier as chief credit officer
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance